Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.

J Cancer Res Clin Oncol · 2022 · PMC9349099 · PMID 34541612

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

marginally non-significantp = 0.065so close (0.05 < p ≤ 0.1)

Additionally, although the difference was marginally non-significant, patients with ECOG-PS ≥ 1 had shorter overall survival (HR, 1.3 [95% CI, 0.98–1.7]; p = 0.065).

also in 1,493 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.